Albireo Pharma (ALBO) Received its Third Buy in a Row

After Needham and H.C. Wainwright gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos maintained a Buy rating on Albireo Pharma today and set a price target of $60.00. The company’s shares closed last Monday at $18.66.

According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -21.6% and a 24.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Albireo Pharma has an analyst consensus of Strong Buy, with a price target consensus of $52.75.

See today’s analyst top recommended stocks >>

The company has a one-year high of $38.69 and a one-year low of $11.26. Currently, Albireo Pharma has an average volume of 117.7K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALBO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.